Pretreatment lactate dehydrogenase may predict outcome of advanced non small‐cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysis
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The main aim of this study is to investigate whether baseline lactate dehydrogenase (LDH) is associated with the clinical outcome of non small‐cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs). We searched Pubmed, the Cochrane Central library and Embase for peripheral blood biomarker of LDH in advanced NSCLC patients treated with ICIs. We extracted the hazard ratio (HR) with 95% confidence interval (CI) for the progression free survival (PFS) and overall survival (OS) and performed meta‐analysis of HR. Pooled estimates of treatment outcomes were calculated by stata 15.1. Six studies with 1136 patients were included in this study. The pooled results of univariate analysis suggested that an elevated pretreatment LDH level was correlated with significant shorter PFS (HR = 1.53, 95% CI 1.27‐1.83, P < 0.001) and OS (HR = 2.11, 95% CI 1.43‐3.11, P < 0.001). The association remained significant in the multivariate analysis that elevated pretreatment LDH level was associated with poor PFS (HR = 1.62, 95% CI 1.26‐2.08, P < 0.001) and OS (HR = 2.38, 95% CI 1.37‐4.12, P = 0.002). A high pretreatment LDH level was significantly correlated with shorter PFS and OS. Pretreatment LDH may serve as a predictive biomarker for advanced NSCLC patients treated with ICIs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Nishino, M., Ramaiya, N. H., Hatabu, H., & Hodi, F. S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.88 · Cited by 1,023
Mezquita, L., Auclin, E., Ferrara, R., Charrier, M., Remon, J., Planchard, D., Ponce, S., Ares, L. P., Leroy, L., Audigier-Valette, C., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4771 · Cited by 913
Cited by
Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches
de la Cruz-López, K. G., Castro-Muñoz, L. J., Reyes-Hernández, D. O., García-Carrancá, A., & Manzo-Merino, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01143 · Cited by 940
Energy metabolism in health and diseases
Liu, H., Wang, S., Wang, J., Guo, X., Song, Y., Fu, K., Gao, Z., Liu, D., He, W., & Yang, L.-L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02141-x · Cited by 399
Self-citationLactate in the Tumor Microenvironment: An Essential Molecule in Cancer Progression and Treatment
Pérez-Tomás, R., & Pérez-Guillén, I. (2020) · Cancers · doi:10.3390/cancers12113244 · Cited by 385
The multiple roles of LDH in cancer
Claps, G., Faouzi, S., Quidville, V., Chehade, F., Shen, S., Vagner, S., & Robert, C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00686-2 · Cited by 351
Tumour burden and efficacy of immune-checkpoint inhibitors
Dall’Olio, F. G., Marabelle, A., Caramella, C., Garcia, C., Aldea, M., Chaput, N., Robert, C., & Besse, B. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00564-3 · Cited by 350
Zhang, N., Jiang, J., Tang, S., & Sun, G. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106677 · Cited by 109
Metadata
- Authors
- Zhang, Z., Li, Y., Yan, X., Song, Q., Wang, G., Hu, Y., Jiao, S., & Wang, J.
- Venue
- Cancer Medicine
- Publisher
- Wiley
- Published
- 2019-03-07
- Volume
- 8
- Issue
- 4
- Pages
- 1467-1473
- ISSN
- 2045-7634 (ISSN-L)
- OpenAlex
- W2921283714
- Cited by
- 156
- References
- 2
- FWCI
- 7.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.